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Abstract 
 PURPOSE: The present work reports the study of different 
proportion of Lamivudine: Methocel K15M formulations, inorder to 
investigation the effect of polymer proportion and diluent on the drug release 
mechanism. Lamivudine, an anti-HIV agent, was used as a model drug to 
evaluate its release characteristics from different matrices.  
METHOD: Matrix tablets of Lamivudine were prepared by direct 
compression process using methocel K15M CR polymer. In vitro release 
studies were performed using US Pharmacopeia type 1 apparatus (basket 
method) in 900 mL of pH 6.8 phosphate buffer at 100 rpm for 8 hours (Initial 
2 hours in simulated gastric fluid (pH 1.2)). Scanning Electron Microscopy 
(SEM) was used to evaluate and surface properties of the matrices. Drug 
release was analyzed according to their kinetic models. A one-way analysis 
of variance (ANOVA) was used to interpret the results. 
RESULTS: Statistically significant differences were found among the drug 
release profile from different formulations. Higher proportion of polymeric 
content (25 to 30% of the total tablet weight) in the matrix, release was 
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extended > 8 hours due to increased tortuosity and decreased porosity. At 
lower proportion of polymeric content (10% of the total tablet weight), the 
rate of drug release was elevated. Two formulations showed drug release is 
more controlled. The release mechanism was explored and explained with 
zero order, first order, Higuchi and Korsmeyer and Hixon-Crowell equations.  
CONCLUSION: The results generated in this study showed that the profile 
and kinetics of drug release were functions of polymer type, polymer level 
and physico-chemical properties of the drug. By suitable modulation could 
be developed controlled delivery of such type of drug. 
 
Keywords: Lamivudine, methocel K15M CR, matrix tablets, sustained 
release 
 
INTRODUCTION 
 AIDS is considered to be an epidemic, and according to estimates 
from the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the 
World Health Organization (WHO) AIDS Epidemic Update 2005, 38 million 
adults and 2.3 million children were living with the human 
immunodeficiency virus (HIV) at the end of 2005. The annual number of 
AIDS deaths can be expected to increase for many years to come, unless 
more effective and patient-compliant antiretroviral medications are available 
at affordable prices (Joint United Nations Programme, 2006).  The major 
drawbacks of antiretroviral drugs for the treatment of AIDS are their adverse 
side effects during long-term therapy, poor patient compliance, and their 
huge cost (Zhou et al., 2007 ; Castillo et al., 2006)  
 Lamivudine is a synthetic nucleoside analog that is being 
increasingly used as the core of an antiretroviral regimen for the treatment of 
HIV infection (Katlama et al., 1998 ; Merrill et al., 1996).  In vivo, 
nucleoside analogs are phosphorylated intracellularly by endogenous kinases 
to putatively active 5′- triphosphate (3TC-TP) derivatives that prevent HIV 
replication by competitively inhibiting viral reverse transcriptase and 
terminating proviral DNA chain extension (Furman et al., 1986 ; Katy et al., 
1999 ; Becher et al., 2004). Lamivudine is rapidly absorbed after oral 
administration with an absolute bioavailability of 86% ± 16%, peak serum 
concentration of lamivudine (Cmax) of 1.5 ± 0.5 mcg/mL and mean 
elimination half-life (t½) of 5 to 7 hours, thus necessitating frequent 
administration to maintain constant therapeutic drug levels (Himadri et al., 
2005).  
 Therefore, the objective of the present work is to provide a long 
acting pharmaceutical composition containing lamivudine in a sustained 
release matrix formulation, to maintain the blood levels of the active 
ingredient for a prolonged period of time. 
European Scientific Journal   August  2014 edition vol.10, No.24   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
353 
 Oral sustained release dosage form by direct compression technique 
is a simple approach of drug delivery systems that proved to be rational in 
the pharmaceutical arena for its ease, compliance, faster production, avoid 
hydrolytic or oxidative reactions occurred during processing of dosage forms 
(Amidon et al., 2000). Sustained or controlled drug delivery occurs while 
embedded within a polymer that may be natural or semi-synthetic or 
synthetic in nature. The polymer is judiciously combined with the drug or 
other active ingredients in such a way that the active agent is released from 
the material in a predetermined fashion and at constant rate for desired time 
period (Ford et al., 1985). 
 The matrix tablet by direct compression has attracted much attention 
due to its technological simplicity in comparison with other controlled 
release systems. It required fewer unit operations, less machinery, reduced 
number of personnel and processing time, increased product stability and 
production rate (Reddy et al., 2003). A wide array of polymers has been 
employed as drug retarding agents each of which presents a different 
approach to the matrix concept. Polymers that primarily forming insoluble or 
skeleton matrices are considered as the first category of retarding materials 
and are classified as plastic matrix systems. The second class represents 
hydrophobic and water-insoluble materials which are potentially erodable 
and the third group exhibits hydrophilic properties. There are three primary 
mechanisms by which active agents can be released from a delivery system: 
diffusion, degradation and swelling followed by diffusion. The release of 
drug from the tablet matrix depends on the nature of polymer. Methocel 
K15M CR, used in this study is hydrophilic polymer that becomes hydrated, 
swollen and facilitates to diffuse the drug (Vazquez et al., 1992).  
 Matrix based CR tablet formulations are the most popular and easiest 
to formulate on a commercial scale. The matrix can be prepared via wet 
granulation or by direct compression (Vargas et al., 199). 
 
MATERIALS AND METHODS 
Materials 
 Lamivudine was obtained as gift sample from Beximco 
Pharmaceuticals Ltd. Tongi, Bangladesh. HPMC (Methocel K15M CR) was 
a gift sample received from Colorcon Asia Pvt.Limited. Avicel pH 102 was 
purchased from Ming Tai Chemical Co.Ltd., (Taiwan). Magnesium stearate 
and talc were  procured from Hanua Chemicals Limited, (Japan). 
 
Preparation of matrix tablets 
 Tablets were prepared by direct compression process. In all cases, the 
amount of the active ingredient was 200 mg and the total weight of the tablet 
was 400 mg (Table-1).  
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Table 1. Formulation of Lamivudine sustained release matrix tablets 
Formulation 
Code 
Weight (mg) / Tablet 
Methocel 
K15M CR 
Lamivudine 
mg 
Avicel 
PH 102 Talc 
Mg - 
stearate 
Total 
mg 
LAMF1 40 200 144 12 4 400 
LAMF2 60 200 124 12 4 400 
LAMF3 80 200 104 12 4 400 
LAMF4 100 200 84 12 4 400 
LAMF5 120 200 64 12 4 400 
 
 During granulation process matrix-forming agents, talc, methocel, 
magnesium stearate, avicel pH 102 and the active ingredient were weighed 
properly. Firstly active ingredient, talc and Methocel were mixed for 10 
minutes properly. Dried granules were sieved through 20 mesh SS screen to 
get compressible particle. Lubricants are added during blending part. During 
blending total mass was taken in a container and blended in a laboratory 
designed small drum blender machine for about 30 minutes. Particular 
attention was given to ensure thorough mixing and phase homogenization. 
Finally, the prepared granules were compressed using Pressima D type 4-
station compression machine with a 10.00 mm punch. Before compression, 
the surfaces of the die and punch were lubricated with purified talc. All the 
preparations were stored in airtight containers at room temperature for 
further study. 
 
Control tests for matrix tablets 
 The tablets of the proposed formulations (LAMF1 to LAMF5) were 
evaluated for hardness, weight variation, thickness, friability and drug 
content. Hardness of 10 matrix tablets from each formulation was measured 
using Hardness tester (Erweka GMBH, 300H model, Germany). Friability of 
the tablets was determined by testing 10 tablets in a Roche friabilator 
(Campbell Electronics, Mumbai) for 4 minutes at 25 rpm. A slide calipers 
was used to measure the thickness for 5 tablets.  Weight variation test was 
performed by taking 10 tablets using an electric balance (OHAUS LS 200, 
Switzerland) according to the official method. Drug content for Lamivudine 
was carried out by measuring the absorbance of the sample at 271 nm using 
Shimadzu 1240 UV visible spectrophotometer, Japan and comparing the 
content from a calibration curve prepared with standard Lamivudine in the 
same medium by taking 20 tablets were taken, weighed and finely powdered. 
An accurately weighed quantity of this powder was taken, suitably dissolved 
in pH 6.8 phosphate buffer, making dilution and analyzed and carried out in 
triplicate and mean was taken. 
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In vitro dissolution study of tablets 
 Dissolution studies were conducted using a tablet dissolution tester 
(Dissolution Tester [US Pharmacopeia] VEEGO VDA 8 DR, Germany), 
type 1 (basket method), in 900 mL of pH 6.8 phosphate buffer at 37.5°C ± 
0.5°C. The stirring speed was set at 100 rpm. At predetermined time 
intervals, a 10-mL sample was withdrawn and replaced with fresh 
dissolution medium. After filtration and appropriate dilution, the sample 
solution was analyzed at 271 nm for Lamivudine by UV spectrophotometer 
(Shimadzu 1240, UV visible spectrophotometer, Japan). The amounts of 
drug present in the samples were calculated with the help of straight-line 
equation obtained from the calibration curves for respective drug. The mean 
of six tablets from each formulation was used in data analysis. The 
dissolution study was continued for 8 hours (Initial 2 hours in simulated 
gastric fluid (pH 1.2) and next 6 hours in phosphate buffer of pH 6.8 ) to get 
a simulated picture of the drug release in the in-vivo condition and drug 
dissolved at specified time periods was plotted as percent release versus time 
(hours) curve. This drug release profile was fitted into several mathematical 
models to get an idea of the release mechanism. 
 
Kinetic modeling of the drug release 
 Different kinetic models (zero-order, first-order, Higuchi’s , 
korsmeyer’s and Hixon Crowell) were applied to interpret the release profile 
from matrix system. To study the mechanism of drug release from the matrix 
tablets, the release data were fitted to zero-order, first-order, and Higuchi 
equation. However, two factors diminish the applicability of Higuchi’s 
equation to matrix systems. This model fails to allow the influence of 
swelling of the matrix (upon hydration) and gradual erosion of the matrix. 
Therefore, the dissolution data were also fitted according to the well-known 
exponential equation (Korsmeyer equation), Eq. (1), which is often used to 
describe the drug release behavior from polymeric systems (Korsmeyer et 
al., 1983).  
Log ( Mt / Mf ) = Log k + n Log t  …………. (1) 
 Where, Mt is the amount of drug release at time t; Mf is the amount 
of drug release after infinite time; k is a release rate constant incorporating 
structural and geometric characteristics of the tablet; and n is the diffusional 
exponent indicative of the mechanism of drug release. To clarify the release 
exponent for different batches of matrix tablets, the log value of percentage 
drug dissolved was plotted against log time for each batch according to the 
equation 1. A value of n = 0.45 indicates Fickian (case I) release; >0.45 but 
<0.89 for non-Fickian (anomalous) release; and >0.89 indicates super case II 
type of release. Case II generally refers to the erosion of the polymeric chain 
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and anomalous transport (non-Fickian) refers to a combination of both 
diffusion and erosion controlled-drug release (Shato et al., 1997). 
 The Hixon - Crowell cube root equation is: 
M1/3 = Mo1/3  – Kct ———————————————    (2) 
 Where, Kc is the cube root dissolution rate constant. Cube roots of 
percent releases (Cube root of initial drug load minus cube root of % drug 
remaining) are plotted against time (hour) to demonstrate the Hixson Crowell 
plot. 
Mean dissolution time (MDT) was calculated from dissolution data 
using the following equation (Mockel et al., 1997).  
MDT= ( n / n+1 ).K -1/n ……………. (3) 
 
Scanning Electron Microscopy 
 Then tablets were position into sample holder to the microscope and 
visualized under scanning electron microscope (SEM), (HITACHI, Model: 
S-3400N). Tablets were taken using different magnifications. The 
magnifications used for taking tablets were 100-10000 (SE-Secondary 
Electron). 
 
Statistical Analysis:  
 A one way analysis of variance (ANOVA) was used to analyze the 
dissolution data obtained for each batch of formulation to compare the drug 
release rate and comparison of mean dissolution time (MDT) of all 
formulations. A confidence limit of P < .05 was fixed and the theoretical 
calculated values of F (Fcrit and Fcal) were compared for the interpretation 
of results. ANOVA was determined using SPSS software (Version 12, SPSS 
Inc., USA). 
 
RESULTS  
Physical Evaluation of Lamivudine matrix tablets 
 The tablets of the proposed formulations (LAMF1 to LAMF5) were 
evaluated for hardness, weight variation, thickness, friability and drug 
content. The thickness (mean ± SD, n=5) of the tablets were (4.71±0.01, 
4.72±0.02, 4.72±0.03, 4.71±0.02, 4.750±0.04 respectively) ranged from 4.71 
to 4.75 mm. The hardness (mean ± SD, n=10) and percentage friability (< 
1%) of the tablets of all batches (6.05±0.27, 6.10±0.27, 6.15±0.27, 6.20±0.27 
and 6.25±0.28 respectively) ranged from 6.05 to 6.25 kg/cm2 and 0.75 to 
0.85 %, respectively. The average percentage weight deviation of 10 tablets 
of each formula was less than ± 5%. Drug content (mean value ± SD within 
0.9) among different batches of tablets ranged from 200.6501mg to 
200.6505mg.  
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Effect of methocel K15M CR on release pattern of Lamivudine 
 Matrix tablets of Lamivudine were formulated using direct 
compression technique. Different methocel K15M CR matrix tablet 
containing Lamivudine as active ingredient having methocel K15M CR 
polymer 10%, 15%, 20%, 25% and 30% respectively of total tablet weight 
(i.e. 20%, 30%, 40%, 50% & 60% respectively of total drug) in the matrix 
tablet with the formulation code LAMF1, LAMF2, LAMF3, LAMF4, 
LAMF5 were prepared to evaluate the effect of this polymer. After 
preparation according to formulation shown in the table 1, their dissolution 
studies were carried out in basket method at 100 rpm in 900ml , phosphate 
buffer ph 6.8 medium at 37 0C (±0.50C). Six tablets from each formulation 
were used in dissolution study. The release profile of Lamivudine was 
monitored up to 8 hours (Initial 2 hours in simulated gastric fluid (pH 1.2) 
and next 6 hours in phosphate buffer of pH 6.8). The average release pattern 
is shown in figure 1.  
 
Figure 1: Zero order plot of release (mean ±SD) of Lamivudine matrix tablets from 
LAMF1(■), LAMF2(□ ), LAMF3(∆), LAMF4(○) and LAMF5(×) formulations. 
 
 A release profile of Lamivudine containing methocel K15M CR 
matrix tablet of five formulations was obtained from the graphs. The total % 
of Lamivudine release (mean value ± SD within 0.9, n = 6) from the 
formulation LAMF1, LAMF2, LAMF3, LAMF4, LAMF5 was 90.52%, 
79.59%, 75.64%, 66.96%, and 57.48% respectively. It has been observed 
that the release rate has been extended with the increase of polymer % and 
with the decrease of avicel percent. The highest percent of drug release 
within 8 hours is obtained from LAMF1 where polymer content is 10% of 
total tablet weight and that of avicel was 36 %. But in LAMF5, the polymer 
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content is 30% of total tablet weight and avicel is 16%, the release of drug is 
controlled with 57.48 % within 8 hours. 
 The rate of drug release was found to be inversely related to the 
amount of methocel K15 M CR present in the matrix structure, i.e. the drug 
release increased with decrease in the polymer content of the matrix tablet. 
The release rate was significantly dependent on the proportion of polymer. A 
statistically significant decrease ( P <.05, Fcrit (4, 25)  =  2.76  and Fcal = 
405.95 ) at the end of first hour, ( P <.05, Fcrit (4, 25) = 2.76  and Fcal = 
2423.87) at the end four hours, ( P <.05, Fcrit (4, 25) = 2.76 and  Fcal = 
884.61) at the end of eight hours,  was observed % drug release in the 
formulation LAMF1 to LAMF5 as the polymer proportion increase from 
10% to 30% of the total drug weight. 
 The release kinetics data has been mention in the table 2. 
Table 2: Release kinetics of formulated Lamivudine from methocel K15M based matrices 
Code 
Zero order First order Higuchi Korsmeyer Hixon Crowell 
 
R2 K o 
% h-1 
R2 K1 
% h-1 
R2 Kh 
% h-0.5 
R2 n R2 Kc 
% h-1 
LAMF1 0.834 9.957 0.989 -0.124 0.979 32.899 0.970 0.455 0.543 0.384 
LAMF2 0.859 8.660 0.976 -0.081 0.991  28.345  0.989 0.453 0.551 0.366 
LAMF3 0.941 8.449 0.989 -0.072 0.996  26.497  0.998 0.561 0.619 0.373 
LAMF4 0.948 7.577 0.991 -0.056 0.995 23.665 0.999 0.583 0.629 0.362 
LAMF5 0.939 6.608 0.985 -0.044 0.996 20.738 0.999 0.586 0.625 0.346 
R2, Correlation coefficients, K0, K1, Kh, Kc Release rate constant for zero order, first order, 
Higuchi, and Hixon Crowell release equation,  respectively, n, diffusional exponent, 
indicative of release mechanism in Korsmeyer equation. LAMF1-LAMF2 = Fickian Release 
(Case I), LAMF3-LAMF5 = Non-Fickian (Anomalous) Release 
 
 T25%, T50%,  T80% and MDT values of the designed tablets are also 
shown in figure 2.  
 
Figure 2:  Successive dissolution time [T25%( ) , T50%(■), T80%(□), MDT Value( )] of 
Lamivudine containing Methocel K15M matrices 
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 In case HPMC 15000 cps (methocel K15)  containing formulations, 
formulation LAMF1 showed lowest MDT (mean dissolution time) values of 
all as it increased the release rate. But, as the concentration of HPMC 15000 
cps increased in the latter formulations (LAMF2, LAMF3, LAMF4, 
LAMF5), MDT values were increased i.e increase polymer load increase 
MDT value. Formulation LAMF5 showed highest MDT (7.4 hr) value.  The 
MDT values increased significantly P < .05, Fcrit (4, 25) = 2.76 and Fcal = 
701.21 ) as polymer load was increased 10% to 30% of the total drug weight. 
 
Scanning electron microscope analysis 
 Matrix tablets were prepared at different concentration of methocel 
K15M CR polymer and different exepients like avicel PH102, talc, 
magnesium stearate. Morphology and surface properties of the tablets were 
examined with a Scanning Electron Microscope “SEM” (Fig.-3) (HITACHI, 
Model: S-3400N). Tablets were taken using different magnifications.  
 The magnifications used for taking tablets were 100-10000 (SE-
Secondary Electron). Morphology and surface properties of the tablets were 
found to be affected by the polymer concentration. 
 
Figure 3: SEM of Methocel K15M CR on Lamivudine sustained release Tablets 
A. 100 SE(Magnification x 100)           D. 2.00k SE(Magnification x 2000) 
B. 500 SE(Magnification x 500)           E. 5.00k SE(Magnification x 5000) 
C. 1.00k SE(Magnification x 1000)      F. 10.0k SE(Magnification x 10000) 
 
Figure: 1. SEM Photographs of Lamivudine showing surface morphology 
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DISCUSSION 
Physical Evaluation of Lamivudine matrix tablets 
 The present study was carried out to formulate oral sustained release 
drug delivery system for Lamivudine as Matrix Tablets. The drug content of 
all formulations was between 100.32 and 100.33 %, indicating the presence 
of an acceptable amount of drug in the formulations. Furthermore, all the 
formulations showed acceptable hardness and friability.  
 
In vitro dissolution study of tablets 
 The formulations, LAMF1 LAMF2 showed initial burst release 
within the 2-hour dissolution test period in pH 1.2 buffer. This phenomenon 
may be attributed to surface erosion or initial disaggregation of the matrix 
tablet prior to gel layer formation around the tablet core (Ebube et al., 1997).  
 However the later formulations LAMF3 to LAMF5 containing higher 
proportion of methocel K15  polymer no burst release was observed within 
two hours probably to the low solubility of the drug at pH 1.2 and retained 
their shape throughout the 8 hour dissolution period . they showed slow drug 
release from 0 to 2 hours followed  by faster but controlled release from  3rd  
to 8th hour.  
 The release rate decreased and the drug release prolonged as the 
polymer proportion was increase. Such increase in polymer content results in 
a decrease in the drug release rate due to a decrease in the total porosity i.e. 
release is extended to long period. Avicel causes a decreased tortuosity of the 
path of the drug due to its preferential solubility than methocel K15 M CR, 
by its swelling effect, additionally weakened the integrity of the matrix.  
 For the formulation LAMF5 containing highest proportion of 
polymer drug release is more controlled both pH 1.2 (less than 20% in acidic 
media) and phosphate buffer pH 6.8 ( extended more than 8 hours). This may 
be owing to a more rigid complex formed by presence of higher proportion 
of HPMC which helped in retaining the drug in matrix and did not allow 
rapid diffusion of drug from the matrix. 
 Among these formulations (LAMF1 to LAMF5), the rate and extent 
of drug release was decreased with increasing the amount of Methocel 
K15M CR. This polymer has been well known to retard the drug release by 
swelling in aqueous media. A polymer’s ability to retard the drug release rate 
is related to its viscosity. Processing factors including particle size, hardness, 
porosity and compressibility index etc. also can affect the release rate of drug 
from tablets. The hydration rate of HPMC depends on the nature of the 
substituents like hydroxypropyl group content. Hence, Methocel K15M CR 
was used because it forms a strong viscous gel in contact with aqueous 
media, which may be useful in controlled delivery of drug (Hogan, 1989). 
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Kinetic modeling of the drug release 
 The drug release data obtained were extrapolated by Zero order, First 
order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell equations to know 
the mechanism of drug release from these formulations. In this experiment, 
the in vitro release profiles of drug from all these formulations could be best 
expressed by Higuchi’s equation as the plots showed highest linearity ( R2: 
0.98 to 0.99). To confirm the diffusion mechanism, the data were fitted into 
Korsmeyer-Peppas equation (Korsmeyer et al., 1983). The formulations 
showed good linearity (R2:0.97 to 0.99) with slope (n) values ranging from 
0.4527 to 0.5856 indicating that diffusion was the predominant mechanism 
of drug release from these formulations indicating that the release 
mechanism was non-Fickian or anomalous release (0.45 < n <0.89). It can be 
inferred that the release was dependent on both drug diffusion and polymer 
relaxation, which appears to indicate a coupling of diffusion and erosion 
mechanisms-so called anomalous diffusion (Peppas, 1985), when plotted 
according to Korsmeyer-Peppas equation, the formulationsLAMF4 to 
LAMF5 showed highest linearity (R2: 0.999). The poor correlation 
coefficients (R2 values ranged from 0.83 to 0.94) observed for the kinetic 
parameters based on the zero-order model equation were mainly due to the 
drug release mechanism. First order plot for all formulation showed good 
linearity. The release profile of Lamivudine from all these formulations 
displayed very poor fitting with Hixson-Crowell cube root model of drug 
release, which were related, with the method of manufacture followed. 
 
Scanning electron microscope analysis (SEM ) 
 Study further confirmed both diffusion and erosion mechanisms to be 
operative during drug release from the surface of matrix tablet. Morphology 
and surface properties of the tablets were found to be affected by the 
polymer concentration. 
 
CONCLUSION 
 From the study, it is possible to conclude that the selected excipients 
are likely to be suitable for the preparation of tablet formulations direct 
compression method. According to the release studies, formulations 
containing low level of polymer are not appropriate for the preparation of 
modified hydrophilic matrix tablets while higher level may be advantageous 
as release rate of the drug from matrix tablets was dependent on the 
proportion and type of the polymer used. The results of release studies 
indicated the possibility of achieving a suitable modulation of Lamivudine 
release rate by opportunely varying the methocel K15M CR in the matrix 
tablet. 
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